Gregory S. Moss
Known title: Chief Business & Legal OfficerCIK: 0001742496
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Evommune to Present Phase 2a Data for EVO301 at EADV Congress. Evommune will present late‑breaker Phase 2a results for its atopic dermatitis drug EVO301 at the European Academy of Dermatology & Venereology Congress. The presentation follows a setback with its earlier candidate EVO756, shifting focus to the more promising EVO301. The company’s pipeline reset underscores the importance of these data for its future prospects.
Transaction History
| AVR | ▲ Buy | Option Exercise | 17,580 | — | 6/7/2026 | View on chart |
| EVMN | ▲ Buy | Option Exercise | 14,223 | $24K | 5/28/2026 | View on chart |
| EVMN | ▼ Sell | Open Market | 14,223 | $325K | 5/28/2026 | View on chart |
| EVMN | ▼ Sell | Tax Withholding | 13,624 | $243K | 12/9/2025 | View on chart |
| EVMN | ▼ Sell | Other | 3,175 | — | 11/7/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Cantor Fitzgerald Upgrades Anteris Technologies, Sets $15 Target
Cantor Fitzgerald reiterated an overweight rating for Anteris Technologies Global Corp. The brokerage maintained a $15 price target, matching the current analyst consensus. The upgrade comes as the stock trades near its 52‑week low and a low RSI, indicating potential upside.
Cantor Fitzgerald Upgrades Anteris Technologies, Sets $15 Target. Cantor Fitzgerald reiterated an overweight rating for Anteris Technologies Global Corp. The brokerage maintained a $15 price target, matching the current analyst consensus. The upgrade comes as the stock trades near its 52‑week low and a low RSI, indicating potential upside.